RxDoctor Payments Data

Mujtaba Khan, MD

Clinical Cardiac Electrophysiology · Dayton, OHNPI 1629047857

Payments from drug & device makers

$6,431in general payments, 2019–2025

Across 111 payments — averaging $57.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$3K
  • Boston Scientific$2K
  • Novartis$273
  • AstraZeneca$229
  • Amgen$153
  • Boehringer Ingelheim$150
  • plus $670 from 12 others

What the payments were for

  • Travel & lodging$3,03947%
  • Food & beverage$3,27851%
  • Education$1142%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,431 in reported general payments places this provider in the 20th percentile of 159 clinical cardiac electrophysiology providers in Ohio.

See all clinical cardiac electrophysiology providers in Ohio

Medicare billing

Part B allowed, 2024
$151,317
Medicare patients
323
Services billed
1,612

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban183$175,531
JardianceEmpagliflozin87$77,636
EntrestoSacubitril/Valsartan58$60,424
XareltoRivaroxaban21$22,251
BrilintaTicagrelor19$15,543
FarxigaDapagliflozin Propanediol12$13,106
MultaqDronedarone Hcl12$9,419
Repatha SyringeEvolocumab12$6,603
Metoprolol Succinate279$2,985
Diltiazem 12hr ErDiltiazem Hcl17$1,623
Amiodarone Hcl67$1,491
Diltiazem 24hr Er (Cd)Diltiazem Hcl46$968
Isosorbide Mononitrate ErIsosorbide Mononitrate66$548
Potassium Chloride42$524
Losartan Potassium93$521

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$57$175,531183 claims
Boehringer IngelheimJardiance$150$77,63687 claims
NovartisEntresto$273$60,42458 claims
AstraZenecaBrilinta, Farxiga$229$28,65031 claims
Johnson & JohnsonXarelto$18$22,25121 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 159 clinical cardiac electrophysiology providers in Ohio.

Other clinical cardiac electrophysiology in Dayton

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →